Progression-free mesothelioma survival – living with the disease without it becoming worse – remains an elusive goal but that doesn’t mean it is an impossible goal. Top scientific researchers all over the world continue to work towards finding a way to promise progression-free mesothelioma but it remains a matter of experimental trial and error. Clinical trial and error to be exact. You can choose to be part of this process.
On the first Monday of every month we provide you with a National Institutes of Health(NIH)/ National Cancer Institute (NCI)-approved clinical trial that is actively recruiting participants. Find clinical trials we’ve recently posted about here.
NIH’s official site for clinical trials states, “Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.” For general information, see NIH’s Learn About Clinical Studies.
Here is a clinical trial with a stated primary goal of improving the odds of progression-free mesothelioma survival. One of its 145 location sites happens to be right here at the University of California San Francisco, an excellent research and teaching hospital.
Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy – NCT01085630
First received March 11, 2010
Last updated March 11, 2010 (ClinicalTrials.gov processed this record on July 02, 2014)
Sponsor Cancer and Leukemia Group B (a research cooperative group headquartered at the University of Chicago).
Collaborators National Cancer Institute (NCI)
Purpose Pemetrexed disodium, a chemotherapy medication, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This randomized phase II trial is studying how well pemetrexed disodium or observation works in treating patients with malignant pleural mesothelioma without progressive disease after first-line chemotherapy.
Discussion of Outcome Measures Progression-free mesothelioma survival is the primary outcome measure. After completion of study therapy, patients are followed up every 6 months for 3 years.
Estimated Enrollment 96
Study Start Date April 2010
Primary Completion Date December 2015
Eligibility Confirmed malignant pleural mesothelioma not amenable to surgery; prior surgery and prior radiation treatment okay. Additional eligibility criteria here.
Contacts and Locations UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA94115; Clinical Trials Office 877-827-3222 Show 145 Study Locations